Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 11/20 | 0.79 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.52 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.51 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13159659 | 0.89 | HDAC1 (1.00) | HDAC1HDAC8HDAC4MEF2DHDAC6 | |
| SCHEMBL8344769 | 0.89 | HDAC1 (1.00) | HDAC1HDAC8HDAC4MEF2DHDAC6 | |
| SCHEMBL10420281 | 0.89 | HDAC1 (0.73) | HDAC1HDAC8 | |
| SCHEMBL13159719 | 0.85 | HDAC1 (0.87) | HDAC1HDAC8HDAC4MEF2DHDAC6 | |
| SCHEMBL8094598 | 0.84 | HDAC1 (0.76) | HDAC1HDAC8HDAC4HDAC6HDAC3 | |
| SCHEMBL8420871 | 0.83 | HDAC1 (0.65) | HDAC1HDAC4MEF2DPABPC1MEN1 | |
| SCHEMBL8374731 | 0.82 | HDAC1 (0.62) | HDAC1PABPC1MEN1NPC1POLB | |
| SCHEMBL8094435 | 0.82 | HDAC8 (0.71) | HDAC1HDAC8HDAC4HDAC6HDAC3 | |
| SCHEMBL8083026 | 0.81 | HDAC1 (0.79) | HDAC1HDAC8HDAC4MEF2DHDAC6 | |
| SCHEMBL8312496 | 0.80 | HDAC1 (0.61) | HDAC1HDAC8HDAC4MEF2DHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041067-A1 | Methods of Inducing Terminal Differentiation | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2012-02-16 | — | — | US | disclosed |
| US-8101663-B2 | Polymorphs of suberoylanilide hydroxamic acid | MERCK HDAC RESEARCH, LLC (US) | 2012-01-24 | — | — | US | disclosed |
| US-8067472-B2 | Methods of treating Hodgkin's and non-Hodgkin's lymphoma | MERCK HDAC RESEARCH, LLC (US) | 2011-11-29 | — | — | US | disclosed |
| US-7851509-B2 | Polymorphs of suberoylanilide hydroxamic acid | MERCK HDAC RESEARCH, LLC (US) | 2010-12-14 | — | — | US | disclosed |
| US-7847122-B2 | Polymorphs of suberoylanilide hydroxamic acid | MERCK HDAC RESEARCH, LLC (US) | 2010-12-07 | — | — | US | disclosed |
| US-20100273732-A1 | COMBINATION METHODS OF TREATING CANCER | BACOPOULOS NICHOLAS G | 2010-10-28 | — | — | US | disclosed |
| US-20100210729-A1 | Methods of inducing terminal differentiation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-08-19 | — | — | US | disclosed |
| US-20100168242-A1 | Polymorphs of suberoylanilide hydroxamic acid | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-07-01 | — | — | US | disclosed |
| US-7732490-B2 | Methods of treating cancer | MERCK HDAC RESEARCH, LLC (US) | 2010-06-08 | — | — | US | disclosed |
| US-7652069-B2 | Polymorphs of suberoylanilide hydroxamic acid | MERCK HDAC RESEARCH, LLC (US) | 2010-01-26 | — | — | US | disclosed |
| US-20080194692-A1 | Polymorphs of suberoylanilide hydroxamic acid | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-08-14 | — | — | US | disclosed |
| US-7399787-B2 | Methods of treating cancer with HDAC inhibitors | MERCK HDAC RESEARCH, LLC (US) | 2008-07-15 | — | — | US | disclosed |
| US-20080119562-A1 | Methods of Inducing Terminal Differentiation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-05-22 | — | — | US | disclosed |
| US-7375137-B2 | Methods of treating cancer with HDAC inhibitors | MERCK HDAC RESEARCH, LLC (US) | 2008-05-20 | — | — | US | disclosed |
| US-20080114069-A1 | Methods of inducing terminal differentiation | RICHON VICTORIA M | 2008-05-15 | — | — | US | disclosed |
| US-20070190022-A1 | Combination methods of treating cancer | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-08-16 | — | — | US | disclosed |
| US-20070060614-A1 | Methods of treating cancer with hdac inhibitors | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-03-15 | — | — | US | disclosed |
| US-20060167103-A1 | Methods of treating cancer with HDAC inhibitors | ATON PHARMA, INC. (US) | 2006-07-27 | — | — | US | disclosed |
| US-20040132825-A1 | Methods of treating cancer with HDAC inhibitors | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2004-07-08 | — | — | US | disclosed |
| US-20040127523-A1 | safe, daily dosing regimen of histone deacetylase (HDAC) inhibitors having favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blood levels of the active compounds over an extended period of time | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167103-A1 | Methods of treating cancer with HDAC inhibitors | HDAC5, HDAC1, HDAC4 | HDAC1 2/4885HDAC8 10/4885HDAC4 3/4885 |
| US-20080119562-A1 | Methods of Inducing Terminal Differentiation | HDAC3, HDAC1, HDAC5 | HDAC1 2/4885HDAC8 9/4885HDAC4 5/4885 |
| US-20040127523-A1 | safe, daily dosing regimen of histone deacetylase (HDAC) inhibitors having favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blood levels of the active compounds over an extended period of time | HDAC1, HDAC5, HDAC9 | HDAC1 1/4885HDAC8 8/4885HDAC4 5/4885 |
| US-20080194692-A1 | Polymorphs of suberoylanilide hydroxamic acid | HDAC1, HDAC4, HDAC5 | HDAC1 1/4885HDAC8 11/4885HDAC4 2/4885 |
| US-20040132825-A1 | Methods of treating cancer with HDAC inhibitors | HDAC5, HDAC9, HDAC1 | HDAC1 3/4885HDAC8 9/4885HDAC4 4/4885 |
| US-20070060614-A1 | Methods of treating cancer with hdac inhibitors | HDAC5, BCL6, HDAC9 | HDAC1 5/4885HDAC8 14/4885HDAC4 4/4885 |
| US-20100273732-A1 | COMBINATION METHODS OF TREATING CANCER | HDAC5, HDAC1, HDAC4 | HDAC1 2/4885HDAC8 10/4885HDAC4 3/4885 |
| US-20080114069-A1 | Methods of inducing terminal differentiation | HDAC3, HDAC1, HDAC5 | HDAC1 2/4885HDAC8 9/4885HDAC4 5/4885 |
| US-20070190022-A1 | Combination methods of treating cancer | HDAC5, HDAC1, HDAC4 | HDAC1 2/4885HDAC8 10/4885HDAC4 3/4885 |
| US-20100210729-A1 | Methods of inducing terminal differentiation | HDAC3, HDAC1, HDAC5 | HDAC1 2/4885HDAC8 9/4885HDAC4 5/4885 |
| US-20100168242-A1 | Polymorphs of suberoylanilide hydroxamic acid | HDAC1, HDAC4, HDAC5 | HDAC1 1/4885HDAC8 11/4885HDAC4 2/4885 |
| US-20120041067-A1 | Methods of Inducing Terminal Differentiation | HDAC3, HDAC1, HDAC5 | HDAC1 2/4885HDAC8 9/4885HDAC4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.